Charles Schwab Investment Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 0.7% during the third quarter, Holdings Channel.com reports. The institutional investor owned 418,980 shares of the biopharmaceutical company’s stock after purchasing an additional 2,836 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $74,201,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Parnassus Investments LLC bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $6,862,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Alnylam Pharmaceuticals by 2.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 688,228 shares of the biopharmaceutical company’s stock worth $121,885,000 after buying an additional 15,831 shares in the last quarter. Moody Aldrich Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $404,000. Oppenheimer & Co. Inc. raised its position in shares of Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 93 shares during the period. Finally, Clearstead Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 197.6% during the third quarter. Clearstead Advisors LLC now owns 4,518 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 3,000 shares during the period. 93.98% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Price Performance
Shares of Alnylam Pharmaceuticals stock opened at $169.34 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $148.10 and a 1 year high of $227.91. The firm has a market cap of $21.25 billion, a PE ratio of -40.90 and a beta of 0.43. The stock has a fifty day moving average price of $183.67 and a 200-day moving average price of $179.31.
Analysts Set New Price Targets
In other news, Director Michael W. Bonney sold 30,000 shares of the stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $195.00, for a total transaction of $5,850,000.00. Following the completion of the transaction, the director now owns 16,029 shares in the company, valued at approximately $3,125,655. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.40% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 3 attractive stocks that insiders are buying
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- What Does Downgrade Mean in Investing?
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.